New TPP Still Most Advanced IP Trade Agreement Ever, Think Tank Says 09/03/2018 by William New, Intellectual Property Watch 1 Comment The Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) is on track to offer “the most advanced and detailed standards on intellectual property in a trade agreement to date” despite revisions scaling back the IP chapter after the United States dropped out, says the Washington, DC-based Center for Strategic and International Studies (CSIS).
Pharma, Nonprofits Collaborate On Affordable Hepatitis C Treatment In Latin America 06/03/2018 by Intellectual Property Watch Leave a Comment The Drugs for Neglected Disease initiative (DNDi), a nonprofit research and development organisation, today announced a collaboration with pharmaceutical companies and other nonprofits to manufacture and supply a “new, more affordable” hepatitis C treatment in Latin America. Hepatitis C medicines have been renowned for their high prices worldwide.
A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents.
Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 by Catherine Saez, Intellectual Property Watch 1 Comment The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies.
Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities.
WTO TRIPS Council Looks At IP And The Public Interest, Importance Of Research Exemption 28/02/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment A relatively new topic of discussion at the World Trade Organization committee on intellectual property is the relationship between intellectual property and the public interest. This week, WTO delegates discussed the application and benefits of a regulatory exception to IP rights allowing earlier entry of generics to the market, known as the Bolar exception. The committee also heard about a request from least-developed countries (LDCs) to improve technology transfer measures that developed countries have the obligation to provide under WTO rules.
WTO TRIPS Council: For Some, IP-Intensive Industries Are Engine Of Economy. For Others, IP Alone Is Not Sufficient 28/02/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Trade Organization committee on intellectual property met this week and gave an opportunity to WTO members to discuss the value of intellectual property for micro, small and medium sized enterprises (MSMEs), and its importance for IP-intensive industries. Several members, such as the European Union on behalf of its members presented data to illustrate the importance of IP for MSMEs. Meanwhile, India and South Africa remarked that IP is only one factor to promote innovation, but are not a sufficient ingredient.
WTO, WHO, WIPO Heads Share Views On Innovation And Access At Trilateral Symposium 27/02/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment How to encourage health innovations and make sure that new medicines, vaccines, or diagnostics will reach every person who needs them? That is a question which has been hotly debated in different fora. Yesterday, the World Trade Organization, UN World Health Organization, and UN World Intellectual Property Organization jointly held a symposium on how innovative technologies can promote the United Nations Sustainable Development Goals. The WHO director general called on his colleagues to support policies facilitating access to health technologies.
Wellcome Trust Report Recommends UK-EU Agreement On Research & Innovation 27/02/2018 by William New, Intellectual Property Watch Leave a Comment The Wellcome Trust, the London-based biomedical research charity, has issued recommendations for improved scientific collaboration after Brexit, including to establish a formal agreement on research and innovation. This includes continued leadership by the UK on open research, and might include expanding the UK patent box scheme, it says.
Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 by Catherine Saez and William New, Intellectual Property Watch Leave a Comment Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it.